Cuba launches clinic for chikungunya aftereffects

The Institute of Neurology and Neurosurgery in Cuba has begun a specialized clinic to care for patients with post-chikungunya ailments, particularly those linked to neuropathic pain, joint pain, and paresthesia. This step provides focused treatment for individuals impacted by the mosquito-borne virus.

In Havana on December 23, the Institute of Neurology and Neurosurgery in Cuba has launched a specialized clinic dedicated to treating patients with post-chikungunya ailments. The facility focuses on conditions such as neuropathic pain, joint pain, and paresthesia, which are common lingering effects of the mosquito-borne chikungunya virus that causes fever and severe aches.

Chikungunya can lead to long-term complications that impair daily life for those infected. The new clinic aims to address these persistent issues through comprehensive care. As reported by Prensa Latina, this opening meets the demand for specialized health services in Cuba.

While specific patient numbers are not yet available, the clinic is part of Cuba's public health efforts to manage infectious diseases and their neurological aftermaths. This initiative highlights Cuba's dedication to accessible medical treatment for virus-related conditions.

Related Articles

Comparative illustration of long COVID patients: US woman with severe brain fog and anxiety versus milder symptoms in India, Nigeria, and Colombia, per international study.
Image generated by AI

International study finds U.S. long COVID patients report more brain fog and psychological symptoms than peers in India and Nigeria

Reported by AI Image generated by AI Fact checked

A Northwestern Medicine-led study of more than 3,100 adults with long COVID found that non-hospitalized participants in the United States reported substantially higher rates of brain fog, depression/anxiety and insomnia than participants in Colombia, Nigeria and India—differences the researchers say likely reflect cultural factors and access to care as much as biology.

Cuban President Miguel Díaz-Canel presented preliminary positive results from clinical trials of the biotechnological drug Jusvinza in patients with chronic post-chikungunya arthritis. The studies, started in December 2025, show notable improvements in provinces like Havana and Matanzas. Experts highlight the drug's safety profile and potential to slow inflammation.

Reported by AI

Cuba has a favorable epidemiological situation in its fight against arboviruses, following a 21 percent decrease in reported febrile cases last week. This improvement highlights effective efforts to control vector-borne diseases such as dengue and zika. Health authorities emphasize the need for ongoing vigilance.

A genetic technology called a gene drive has shown promise in preventing malaria transmission by mosquitoes during lab tests in Tanzania. Researchers modified local mosquitoes to produce antimalarial proteins, demonstrating effective inhibition of parasites from infected children. The findings suggest the approach could work in the field if released.

Reported by AI

Chile's Ministry of Health, through the Public Health Institute, confirmed the detection of the first cases of influenza A (H3N2) sub-clade K, known as “supergripe”, in analyzed samples in the country. This finding was expected given the virus's global behavior, already detected in Brazil and Peru. Health Minister Ximena Aguilera clarified that it is not a new virus or a pandemic.

Scientists at the University of Queensland have captured the first near‑atomic, high‑resolution 3D images of the yellow fever virus, detailing how the surface of the long‑used vaccine strain differs from virulent, disease‑causing strains. The work sheds light on how the virus is recognised by the immune system and could support improved vaccines for yellow fever and related mosquito‑borne diseases.

Reported by AI

Following initial detections in neighboring South American countries, the H3N2 influenza A K subclade has now reached Argentina, with confirmed cases in Buenos Aires, Santa Cruz, and Neuquén, including hospitalizations for pneumonia. Authorities are advancing the 2026 flu vaccination campaign for at-risk groups, while current vaccines offer partial protection against severe illness, bolstered by antivirals like oseltamivir.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline